The writer is a professor of economics and finance at Columbia University and was chair of the US Council of Economic Advisers under President George W Bush
The Trump administration has wisely emphasised raising America’s rate of economic growth. But growth doesn’t just happen. It is the byproduct of innovation both radical (think of the emergence of generative artificial intelligence) and gradual (such as improvements in manufacturing processes or transport). Many economic factors influence innovation, but research and development is key. While this can be privately or publicly funded, the latter can support basic research with spillovers to many companies and applications.
Therein lies the rub: the new administration’s growth agenda is joined by a significant effort to reduce government spending, spearheaded by the so-called Department of Government Efficiency. Some spending restraint can enhance growth by reducing interest rates or reallocating funds towards more investment-oriented activities. But cuts to R&D, as the administration is advocating at the National Institutes of Health (NIH), National Science Foundation (NSF), Department of Energy (DoE), and Nasa, are counter-productive. They will limit innovation and growth.
The link between R&D and productivity growth has a long pedigree in economics and has generally been acknowledged by US policymakers. In the mid-1950s, economist Robert Solow made the Nobel Prize-winning conclusion that sustained output growth is not possible without technological progress. Decades later, former World Bank chief economist Paul Romer added another Nobel Prize-winning insight: growth reflected the intentional adoption of new ideas, so could be affected by research incentives.
It is well known that research is undervalued by private companies. Private funders of R&D don’t capture all its benefits. The social returns of R&D are two to four times higher than private returns. These high returns are enabled in the US by federal funding. For example, publicly funded research at the NIH has been found to significantly impact private development of new drugs.
In a comprehensive study, Andrew Fieldhouse and Karel Mertens classify major changes in non-defence R&D funding by the DoE, Nasa, NIH and NSF over the postwar period. They estimate implied returns of as much as 200 per cent — raising US economic output by $2 per dollar of funding. This is substantially higher than recent estimates of returns to private R&D. According to the Congressional Budget Office, the high returns to public funding are more than 10 times that on public investment in infrastructure. With the higher tax revenue generated from additional GDP, an increase in R&D funding more than pays for itself.
In aggregate, productivity gains from federal R&D funding are substantial. Indeed, Fieldhouse and Mertens estimate that government-funded R&D amounts to about one-fifth of productivity growth (measured as output growth less all input growth) in the US since the second world war.
Combined with the high social returns of government-funded R&D, it is essential that policymakers in the current administration acknowledge the risks of underfunding R&D. Spending cuts are clearly harmful to productivity and even budget outcomes.
A shift towards government-funded R&D does not imply that policy in these areas should be beyond review. Some economists have questioned whether current R&D projects take sufficiently high scientific risks, particularly on the ideas of younger scholars. And policymakers can certainly investigate whether indirect cost subsidies to universities and laboratories — in addition to the direct costs of research — are set at the appropriate levels. But, if growth is the objective, the presumption must be that additional public spending on R&D is worthwhile.
Federal support for growth-oriented R&D can extend beyond research grants. Publicly supported applied research centres around the country offer a mechanism to collaborate with local universities and business networks to disseminate ideas to practice. This builds upon the agricultural and manufacturing extension services instituted by 19th-century land-grant colleges that enhanced productivity.
The Trump administration is right to promote growth as a public objective. Spending restraint and fiscal discipline can be growth-enhancing. But not all spending is equal. Government-funded R&D is vitally important for innovation and productivity growth. The case is clear.